🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Gabapentin

    Lxo Ireland Designated Activity Company

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  2. Galvokimig, Placebo matching Test 0.9% sodium chloride solution for injection

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  3. Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Astra Zeneca AB

    Recipients of allogeneic stem cell transplantation

    phase 2 small molecule active

    1 trial

  4. Gastrografin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Fecal Impaction

    phase 2 small molecule active

    1 trial

  5. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Pari Pharma GmbH

    Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab

    phase 2 small molecule active

    1 trial

  6. Gentuximab

    Changchun GeneScience Pharmaceutical Co.,

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  7. Gentuximab

    The First People's Hospital of Lianyungang

    Advanced Gastric or Gastroesophageal Junction Cancer

    phase 2 small molecule completed

    1 trial

  8. Glucagon RTU Injection With Insulin Pump Reduction

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  9. Golimumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Placebo for Guselkumab, Golimumab and JNJ-78934804, JNJ-78934804

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  10. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Placebo to Guselkumab and Golimumab and JNJ-78934804, Golimumab, JNJ-78934804

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  11. HEPCLUDEX 2 mg powder for solution for injection, VIR-2218, VIR-3434

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

  12. HH-003(20mg/kg)

    Huahui Health

    Chronic Hepatitis Delta Virus Infection

    phase 2 mab completed

    1 trial

  13. HS_SW01 cells injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ankylosing Spondylitis

    phase 2 small molecule active

    1 trial

  14. HS_SW01 cells injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Ovarian Insufficiency (Poi)

    phase 2 small molecule active

    1 trial

  15. HYCAMTIN 4 mg powder for concentrate for solution for infusion, TAXOL 6 mg/ml, concentrato per soluzione per infusione., Neulasta 6 mg solution for injection, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion

    SUTRO BIOPHARMA, INC.

    Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)

    phase 2 small molecule active

    1 trial

  16. HYDROCORTISONE, PREDNISOLONE ACETATE PH. EUR., ASCIMINIB HYDROCHLORIDE, CYTARABINE, DEXAMETHASONE, BLINATUMOMAB, Asciminib, METHOTREXATE, DBL methotrexate injection, VINCRISTINE SULFATE, DEXAMETHASONE SODIUM PHOSPHATE

    Novartis Pharmaceuticals

    relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

    phase 2 small molecule active

    1 trial

  17. HarMono-T 5 microlitres/mL gas and solvent for dispersion for injection/infusion

    Lacuna Pharma Pty Ltd

    Ultrasound contrast agent, for diagnostic purposes (to assess indeterminate kidney lesions)

    phase 2 small molecule active

    1 trial

  18. Herceptin 150 mg powder for concentrate for solution for infusion, Enhertu 100 mg powder for concentrate for solution for infusion, Fluorouracil Injection, 50 mg/ml, solution for injection, Ziihera 300 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Xeloda 500 mg film-coated tablets, Xeloda 150 mg film-co

    Boehringer Ingelheim

    gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma

    phase 2 small molecule active

    1 trial

  19. Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in

    Sanofi-aventis Healthcare Pty Ltd

    Meningococcal immunization

    phase 2 small molecule active

    1 trial

  20. Human COVID-19 immunoglobulin (pH4) for intravenous injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab active

    1 trial

  21. Humira 40 mg solution for injection in pre-filled syringe

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  22. Humira 40 mg solution for injection in pre-filled syringe, Lutikizumab, Humira 80 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe, Lutikizumab, Humira 40 mg solution for injection in pre-filled syringe, Humira 40 mg solution for injection in pre-filled syringe

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  23. Hyaluronidase

    Amphastar France Pharmaceuticals

    Allergic Skin Reaction

    phase 2 small molecule completed

    1 trial

  24. Hyperimmune plasma

    Lxo Ireland Designated Activity Company

    SARS-CoV 2

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources